GoodRx (GDRX) Expected to Announce Earnings on Thursday

GoodRx (NASDAQ:GDRX) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect GoodRx to post earnings of $0.10 per share and revenue of $199.73 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

GoodRx Stock Up 0.6 %

GDRX opened at $4.84 on Tuesday. The business has a 50 day moving average price of $4.67 and a two-hundred day moving average price of $5.79. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The company has a market cap of $1.84 billion, a PE ratio of -161.33, a P/E/G ratio of 2.46 and a beta of 1.28. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26.

Analysts Set New Price Targets

Several equities analysts have issued reports on GDRX shares. KeyCorp dropped their target price on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Barclays lowered their price target on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Citigroup lowered their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a report on Friday, January 10th. Mizuho initiated coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price target on the stock. Finally, Morgan Stanley lowered their price target on GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 17th. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, GoodRx currently has an average rating of “Moderate Buy” and an average price target of $8.38.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.